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Abstract 
Background: Herpes simplex virus (HSV) is the most common cause of sporadic encephalitis worldwide. The 
high mortality rate (70–80 %) of herpes simplex encephalitis (HSE) can be reduced to 20–30 % by antiviral therapy. 
However, normocellular CSF can lure physicians to look for non-infectious causes, resulting in delayed treatment. 
This study aimed to investigate, characterize and differentiate HSE patients, with normocellular and pleocytosis CSF, 
according to neuroimaging patterns, underlying disease, CSF viral load and clinical outcome. Patients with proven 
(by PCR positive CSF) or presumed viral infections of the CNS admitted to King Chulalongkorn Memorial Hospital 
between January 2002 and 2011 were analyzed.
Results: HSV was detected in the CSF of 43 patients but only 23 patients had encephalitis. Among these 23 patients, 
6 cases (26.1 %) had normal CSF WBC (<5 cells/mm3). One patient in this normocellular CSF group had HIV infection. 
Although this patient had low CD4 counts (<200 cells/mm3), the peripheral WBC counts showed only mild leuko-
penia. The CSF HSV viral load in the pleocytosis group was higher than the normocellular group, with an average of 
12,200 vs 3027 copies/ml respectively. There was no correlation between the viral load and the clinical outcome. With 
respect to neuroimaging, 4 (66.7 %) patients in the normocellular group had unremarkable/non-specific results.
Conclusions: Normocellular CSF in HSE is not rare, and can be seen in normal as well as immunocompromised hosts. 
Clinicians should not exclude CNS infection, especially HSE, merely based on the absence of CSF pleocytosis and/or 
unremarkable neuroimaging study.
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Background
Herpes simplex encephalitis (HSE) caused by herpes 
simplex virus (HSV) is the most common sporadic viral 
encephalitis among adults worldwide [1, 2]. It has been 
responsible for up to 20  % of viral encephalitis cases 
[3]. This disease has a bimodal distribution, where one-
third of the patients are under the age of 20, while the 
remaining are over the age of 50 [4]. Peak incidence is 
around 60–64  years of age. Neither gender, season, nor 
immune status of a patient affects its occurrence. The 
high mortality rate of HSE (70–80 %) can be reduced to 
20–30 % by acyclovir therapy. Acyclovir should be taken 
within 2 days of neurological symptom’s onset as delayed 
treatment can result in severe morbidity and mortality in 
approximately one-third of the patients [5, 6].
HSV-1 is responsible for more than 90  % of HSE in 
adults [7]. Recent studies have demonstrated many 
cases of HSE that resulted from HSV-2 [8, 9]. HSV can 
also be associated with myelitis, radiculitis or both. 
HSV’s preferred areas are the limbic structures, the 
medial temporal cortex and the orbito-frontal regions, 
which are all innervated by branches of olfactory and 
trigeminal nerves. HSV is contracted via contact with 
the mucosal surface of mouth, eye or genitalia, and has 
been speculated to subsequently enter the CNS via any 
nearby sensory nerve ending into these nerves and the 
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corresponding ganglia. Viral entry into the CNS via 
olfactory tract has been substantiated by numerous ani-
mal experiments [10, 11]. However, the neuropathology 
of a mouse brain is more diffused compared to the well-
defined fronto-temporal distribution in a human brain.
HSV can reside in the nerve and can either replicate or 
establish a latent infection [1]. Its DNA can be detected 
in the trigeminal ganglion of previously infected patients. 
At the time of reactivation, latent HSV in the trigeminal 
ganglia can travel along the tentorial nerve that inner-
vates the meninges of the anterior and the middle cranial 
fossa. HSV genomes have also been found in olfactory 
bulb, pons, and the medulla of autopsied brains of nor-
mal individuals [12]. Early gross brain pathology of most 
HSE cases showed hemorrhagic necrosis of the medial 
or the inferior temporal lobe. These lesions were mainly 
bilateral and asymmetrical in distribution. Sub-frontal 
and insular regions were damaged in the latter phase 
[13]. Brain parenchyma in such regions of HSE patients, 
who died after 2 weeks of exhibiting HSE, revealed lique-
faction necrosis.
The cerebral inflammation from glial cells activation, 
due to the presence of HSV, includes increase in expres-
sion of pattern recognition receptors, especially Toll-like 
receptors (TLRs) and interferon regulatory factors (IRFs) 
[4]. Genetic factors, such as deficiency of Toll-like recep-
tor-3 (TLR3), can predispose an individual (especially 
children and young adults) to HSE [10, 11, 14]. Mutation 
of TLR3 and TLR3 pathway genes such as UNC93B1, 
TRIF, TRAF3, and TBK1 can result in the defective pro-
duction of interferon (IFN). Insufficient amount of IFN-β 
and IFN-λ leads to an increase in viral replication and 
enhances cell death. Relapse of HSE tends to occur more 
frequently in those with abnormal TLR3 immunity. How-
ever, these mutations were attributed to only 5 % of HSE 
in children and young adults [11].
The characteristic symptoms of HSE are abnormal 
behavior/psychosis (66  %), confusion/disorientation 
(81 %) and speech disturbance (66 %), which are justifia-
ble due to the preferential involvement of the frontal and 
temporal lobes. Other symptoms of HSE include fever 
(76–90  %), headache (70–90  %) and seizure (50–55  %) 
[5, 15]. However, these symptoms are not unique as they 
can be present in encephalitis caused by other viruses 
[16, 17]. Moreover, these symptoms can also be found 
in immune-mediated encephalitis, in particular the anti-
NMDA receptor encephalitis, which can mimic or occur 
as a relapse encephalitis after the first episode of HSE 
[18].
Hence, diagnosis of HSE requires an integration of 
clinical presentations, neuroimaging, and laboratory 
tests, especially molecular diagnostic techniques. The 
current gold standard confirmatory test for HSE is poly-
merase chain reaction (PCR) to detect HSV DNA in the 
CSF, whose sensitivity is approximately 96 % with a speci-
ficity of 99  % in experienced laboratories [19]. For high 
accuracy of PCR, specimens should be analyzed within 
2–10 days after neurological onset [2].
HSE patients are presumed to have evidence of inflam-
matory response in CNS such as CSF pleocytosis or 
abnormal neuroimaging. CSF pleocytosis in HSE has 
been found in more than 90  % of the patients, with an 
average WBC count of 100–200 cells/mm3 [2, 20]. Major-
ity of the cases (80  %) had mild to moderately elevated 
CSF protein levels (~100  mg/dl), with normal glucose. 
Detection of red blood cells in the CSF was not an indica-
tor of HSV associated CNS infection [19], but may repre-
sent a poor predictor [21]. CSF examination by real-time 
PCR to detect HSV DNA was validated as a new gold 
standard for the diagnosis of HSE in 2004 [2, 19, 22]. 
However, its value in determining viral amount has been 
controversial [21]. Further, there have been increasing 
case reports of normal WBC counts (either normocellu-
lar or acellular) in the CSF of normal and immunocom-
promised HSE patients, and some were associated with 
unremarkable/nonspecific magnetic resonance imaging 
(MRI) findings [15–17, 23].
Methods
Patients with proven (by PCR positive CSF) or presumed 
viral infections of the CNS admitted to King Chulalong-
korn Memorial Hospital (KCMH), Bangkok, Thailand, 
between January 2002 and 2011 were analyzed. Encepha-
litis was defined as clinical evidence of brain parenchy-
mal dysfunction [6], which could not be explained by 
metabolic, electrolyte imbalance, bleeding disorders or 
systemic immune disorders such as systemic lupus ery-
thematosus (SLE), Behcet’s disease or Sjogren syndrome. 
Bacterial, Rickettsial, fungal, tuberculosis and parasitic 
causes were excluded by appropriate clinical and labora-
tory examinations. The diagnosis of HSE was based on 
the clinical features of encephalitis with the exclusion of 
other mimics as described above, and the presence of 
HSV DNA in the CSF.
Retrospective study included those admitted in the 
years 2002–2009 which did not require ethical approval 
or written informed consent based on KCMH ethics 
committee IRB 986/2555. Study on patients admitted in 
the years 2010–2011 was approved by the KCMH eth-
ics committee (Reference no. 015/2011). Informed con-
sent was obtained from these patients in written form; in 
cases where the patient was unable to communicate or 
was underage, consent (and assent where applicable) was 
obtained from a family member, parent or guardian.
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All encephalitis patients with presumed viral causes 
had their CSF examined by PCR for HSV, Varicella zoster 
virus (VZV), Epstein-Barr virus (EBV), Cytomegalovirus 
(CMV) and enteroviruses. Paraneoplastic and autoim-
mune panels as previously described [24] were tested in 
one retrospective patient with normocellular CSF and 
unremarkable brain MRI examination.
PCR technique for HSV DNA
Qualitative real-time PCR [25] was performed on speci-
mens before 2006, where 5 μl of extracted DNA was used 
for amplification and detection. Specimens received year 
2007 onwards, quantitative assay was performed using 
artus® HSV-1/2 LC PCR kit (Qiagen Inc., Valencia, 
CA, USA). DNA from 0.1 to 1 mL of CSF was extracted 
using Nuclisens® extraction kit (bioMérieux, Boxtel, The 
Netherlands). The amplification was undertaken using 
a LightCycler® instrument (Roche Diagnostics, Ger-
many). HSV-1 and -2 DNA PCR product was differenti-
ated by melting curve analysis in the LightCycler® PCR 
instrument. The standard curve was generated from four 
quantitation standards of HSV (10, 100, 1000 and 10,000 
copies/μl) supplied by the manufacturer. Preparation of 
PCR assay, PCR profile and data analysis was conducted 
according to the manufacturer’s protocol. The internal 
control supplied by the manufacturer was included in 
all reactions to check for possible PCR inhibition. The 
analytical detection limit of the PCR Kit was 1 copy/μl 
(p = 0.05) (Qiagen Inc., CA, USA). For qualitative assay, 
all steps were the same as quantitative assay, except that 
the standard curve was not used for calculation, and only 




There were 413 patients with viral neurological infec-
tions during the 10-year period. All had lymphocytic pre-
dominance with normal glucose CSF profile. Those with 
normal CSF cell count were considered encephalitic only 
when their brain dysfunctions could not be explained by 
compromised cardiopulmonary function or other causes. 
One hundred and fifty-eight patients (38.3  %) had viral 
etiologies confirmed by PCR. HSV was detected in the 
CSF of 43 patients (27.2 %) (23 encephalitis and 20 men-
ingitis). Among the 23 HSE patients; there was a slight 
female predominance (1.3:1), ages ranged between 1 and 
85  years [17 (73.9  %) between 16 and 60 (an average of 
36)]. Most of HSE patients were previously healthy except 
2 (8.7 %) with diabetes, 2 (8.7 %) hematologic malignan-
cies, 1 (4.3  %) inactive SLE, 1 (4.3  %) multiple sclerosis 
(MS) and 1 (4.3  %) seropositive for human immune 
deficiency virus (HIV). Most of the patients were from 
central Thailand. The patient with HIV infection was 
diagnosed after hospitalization with acute HSE. Prior 
to hospitalization, the patient had been in good health, 
never received any highly active antiretroviral therapy 
(HAART), and did not have any opportunistic infection. 
The patient’s CD4 count was 200 cells/mm3. The patient 
with MS was in remission and received 50 mg of azathio-
prine daily. Lastly, the patient with inactive SLE had mild 
thrombocytopenia, but was not on any immunosuppres-
sive drugs or corticosteroids.
Clinical findings
Of 23 HSE patients, 16 cases (69.6 %) had fever as a pro-
drome. The most common presenting symptoms were 
seizures (7/23, 30.4 %), behavioral changes (6/23, 26 %), 
alteration of consciousness (5/23, 21.7  %), focal neuro-
logical deficits (3/23, 13 %), and worsening of headaches 
(2/23, 8.7  %). All patients received intravenous admin-
istration of acyclovir. Six patients (26.1  %) recovered 
completely (The Modified Rankin Scale: mRS 0–1), 14 
(60.9  %) partially recovered (mRS 2–3), and 3 patients 
(13 %) died. Demographic data, underlying diseases, and 
presenting symptoms of each group, classified according 
to CSF WBC count, are presented in Table 1.
Laboratory findings
All 23 cases had serum creatinine in the range of 0–3 mg/
dl and normal liver function test. Complete blood count 
data was available in 20 patients, of whom 14 (70  %) 
were within the normal limit, 1 (5 %) had pancytopenia 
(patient no. 17 in pleocytosis group), and 1 (5 %) had leu-
copenia (patient no. 6 in normocellular group). Seven-
teen of 23 patients (73.9 %) had CSF examination within 
2–10 days after neurological symptoms onset, the golden 
period for CSF PCR examination for HSV [7]. CSF find-
ings are detailed in Table  2. CSF protein levels ranged 
between 14 and 528  mg/dl (mean 108.3  mg/dL), while 
CSF glucose levels were between 30 and 139 mg/dl (mean 
66.2 mg/dl). Seventeen patients (73.9 %) had CSF WBC 
counts between 6 and 500 cells/mm3, with lymphocytic 
predominance.
Six cases (26.1  %), with CSF examinations within 
10 days after onset of illness (an average of 3 days), had 
normal CSF WBC (<5 cells/mm3). One patient in this 
normocellular CSF group (16.7  %) had HIV infection. 
Although this patient had low CD4 counts (<200 cells/
mm3), the peripheral WBC counts were 3150 and 3570 
cells/mm3 in two consecutive tests.
Seventeen patients had CSF pleocytosis with CSF WBC 
ranging between 15 and 730 cells (mean 179 cells/mm3), 
3 of whom had CSF WBC count greater than 500 cells/
mm3. Thirteen patients (76.5 %) were previously healthy. 
None of them had HIV infection. CSF HSV viral load in 
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this group was higher than the normocellular group, with 
an average of 12,200 vs 3027 copies/ml respectively. Of all 
14 specimens received after 2007, 10 cases (2 normocel-
lular, 8 pleocytosis) were positive for HSV1 and 4 cases 
(1 normocellular, 3 pleocytosis) were positive for HSV2 
encephalitis. Other CSF parameters are described in 
Table 2.
Imaging findings
Twenty-two patients had complete neuroimaging (either 
computer tomography (CT) or MRI) records. Eleven 
(50 %) patients had the predominant temporal or fronto-
temporal lobe lesions and 2 (9.1 %) had fronto-temporal 
lesion coexisting with thalamic lesions. Another two 
patients had cortical/subcortical (non fronto-temporal) 
lesions. Two patients (9.1  %) had bead-like appearance 
resembling vasculitis on MR angiography, whereas 5 
(22.7 %) had normal or non-specific findings. Brain imag-
ing data altogether with CSF HSV viral load of normocel-
lular and pleocytosis groups are presented in Tables  3 
and 4.
Discussion
In this study, 6 of 23 HSE patients (26.1 %) had normal 
CSF WBC counts as shown in Tables 1 and 2. All nor-
mocellular patients had CSF protein levels less than 
100  mg/dl, whereas half of the patients in the pleocy-
tosis group had CSF protein levels greater than 100 mg/
dl. All brain MRIs of the 15 patients in the pleocytosis 
group, and 2 of 4 patients in the normocellular group 
showed abnormal lesions. Two normocellular patients 
had normal brain MRI and high viral load, 5970 and 
3144 copies/ml respectively. One of them had inactive 
SLE with drowsiness, while the other had MS (in remis-
sion) with behavioral change (Table  4). Two patients 
in the normocellular group had CT scan, which might 
not have been sensitive enough to detect abnormali-
ties, as compared to MRI. However, both did not have 
any other explainable causes. There was no data on CSF 
HSV viral load in both cases as only qualitative PCR 
data was available. One patient was first diagnosed as 
HIV positive at the time of admission with HSE, with 
no history of previous opportunistic infections. HIV 
viral load was not performed in the CSF and data on 
viral load in the blood was not available. Although HIV 
encephalitis could not be excluded, such acute presen-
tation suggests otherwise. Retrospective autoantibody 
test was negative. Both patients had partial recovery 
with acyclovir treatment.
Our study showed that HSE with normocellular CSF 
is more common than what was generally known in 
the past. The CSF protein levels, number of cases with 
abnormal neuroimaging, and CSF viral loads in the 
pleocytosis group were higher when compared to the 
normocellular group. It was noted that CSF viral load 
was up to four times higher in CSF pleocytosis group 
than normocellular group (an average of 12,200 vs 3027 
copies/ml), potentially due to increased inflammatory 
response in pleocytosis group. Viral load alone may not 
entirely explain the magnitude of CSF cellular response, 
as patients with nonspecific MRI in the normocellular 
Table 1 Demographic data and  presenting symptoms 
of  HSV encephalitis in  patients with  CSF pleocytosis 
and patients with normocellular CSF




lar CSF group 
(WBC ≤ 5cells/mm3)
Number of patients 17 6
Male:female 9:8 1:5
Median age (years) [range] 35 [1–59] 41 [27–85]
Underlying disease
 Normal 13 (76.5 %) 3 (50 %)
 HIV infection 0 1 (16.7 %)
 Diabetes mellitus 2 (11.8 %) 0
 Hematologic malignancy 2 (11.8 %) 0
 Multiple Sclerosis (MS) 0 1 (16.7 %)
 Systemic Lupus Erythema-
tosus (SLE)
0 1 (16.7 %)
Prodrome
 Fever 1 (5.9 %) 1 (16.7 %)
 Fever with headache 9 (52.9 %) 1 (16.7 %)
 Fever with myalgia 1 (5.9 %) 1 (16.7 %)
 Upper respiratory tract 
symptoms
1 (5.9 %) 0
 Fever with diarrhea 1 (5.9 %) 0
 Fever with non-specific 
rash
1 (5.9 %) 0
 Headache 2 (11.8 %) 0
 Non-specific 1 (5.9 %) 3 (50 %)
Presenting symptoms
 Worsening headache 
with/without neck 
stiffness
2 (11.8 %) 0
 Hemiparesis 1 (5.9 %) 0
 Facial weakness 1 (5.9 %) 0
 Severe spastic body and 
limbs
1 (5.9 %) 0
 Behavioral change and 
confusion
4 (23.5 %) 3 (50 %)
 Seizures 5 (29.4 %) 2 (33.3 %)
 Alteration of conscious-
ness
3 (17.6 %) 1 (16.7 %)
Outcome
 Complete recovery 5 (29.4 %) 1 (16.7 %)
 Partial recovery 10 (58.8 %) 4 (66.7 %)
 Dead 2 (11.8 %) 1 (16.7 %)
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group also had high copies of viral load. When look-
ing at individual data in normocellular group (Table 4), 
the patient with the highest viral load (5970 copies/
ml) had normal MRI and CSF protein level of 14  mg/
dl. Why some HSE patients have normocellular CSF, or 
normal/nonspecific MRI remains a mystery. Whether 
Table 2 CSF profiles and imaging findings
a Two of the patients (a non fronto-temporal lesion and one with fronto-temporal and thalamic lesions) also had vasculitis, visualized using magnetic resonance 
angiography
b Miscellaneous refers to non-specific lesions such as non-specific white matter changes, aging brain etc
CSF Profile CSF pleocytosis group  
(WBC > 5cells/mm3)
Normocellular CSF group 
(WBC ≤ 5cells/mm3)
Days of CSF examination after neurological onset Day 0—1: 5 (29.4 %)
Day 2—10: 12 (70.6 %)
Day 0—1: 1 (16.7 %)
Day 2—10: 5 (83.3 %)
CSF protein 0–60 mg/dl: 1 (6.3 %)
61–100 mg/dl: 7 (43.8 %)
>100 mg/dl: 8 (50 %)
Not available: 1
0–60 mg/dl: 2 (33.3 %)
61–100 mg/dl: 4 (66.7 %)
>100 mg/dl: 0
CSF glucose <30 mg/dl: 1 (6.3 %)
31–60 mg/dl: 7 (43.8 %)
>60 mg/dl: 8 (50 %)
Not available: 1
<30 mg/dl: 0
31–60 mg/dl 1 (16.7 %)
>60 mg/dl: 5 (83.3 %)
Average CSF viral load 12,200 copies/ml (39–11,755,813  
copies/ml) (11 cases available:  
6 had qualitative test)
3027 copies/ml
(59–5970 copies/ml)
(4 cases available: 3 had qualitative test)
Brain imaging findings 16 available records 6 available records
 Predominant temporal lobe lesions 5 (29.4 %) 1 (16.7 %)
 Fronto-temporal lesions 4 (23.5 %) 1 (16.7 %)
 Other cortical and subcortical lesions (non fronto-temporal)a 3 (18.8 %) 0
 Fronto-temporal and thalamic lesionsa 3 (18.8 %) 0
 Normal or Miscellaneousb 0 2 (33.3 %)
 Normal CT (MRI not performed) 1 (5.9 %) 2 (33.3 %)
Table 3 Individualized data of the CSF pleocytosis group of HSE patients
Patient no. Underlying disease CSF WBC 
(cells/mm3)
Imaging pattern (MRI) CSF HSV viral load  
(copies/ml)
Outcome
1 Normal 230 Fronto-temporal lesions 16,975 Complete recovery
2 Normal 350 Fronto-temporal lesions 2214 Complete recovery
3 Normal 70 Fronto-temporal lesions Qualitative PCR Complete recovery
4 Normal 730 Temporal lobe lesions 11,755,813 Partial recovery
5 Normal 22 Fronto-temporal and thalamic lesions 500,000 Partial recovery
6 Normal 90 Temporal lobe lesions 71,875 Complete recovery
7 Hematologic malignancy 147 Temporal lobe lesions 30,750 Complete recovery
8 Normal 75 Fronto-temporal and thalamic lesions 12,200 Partial recovery
9 DM 510 Other cortical and subcortical lesions 3325 Dead
10 Normal 40 Normal CT 1491 Partial recovery
11 Hematologic Malignancy 40 Other cortical and subcortical lesions 740 Dead
12 Normal 60 Fronto-temporal and thalamic lesions 39 Partial recovery
13 DM 15 N/A Qualitative PCR Partial recovery
14 Normal 600 Temporal lobe lesions Qualitative PCR Partial recovery
15 Old ischemic stroke 22 Fronto-temporal lesions Qualitative PCR Partial recovery
16 Normal 30 Temporal lobe lesions Qualitative PCR Partial recovery
17 Normal 20 Other cortical and subcortical lesions Qualitative PCR Partial recovery
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viral load and/or genetic factors influence inflamma-
tory responses in the CSF or abnormal MRI findings 
is not yet known. Moreover, viral load may not affect 
the outcome, as patients in normocellular group with 
lower viral load were, in fact, more inclined to be more 
severely affected by the disease (one died, four par-
tially recovered, one complete recovery) compared to 
the pleocytosis group, which had higher viral loads on 
average (two died, ten partially recovered, five complete 
recovery). This conformed to a previous study which 
reported no correlation between CSF viral load and 
clinical outcome in HSE patients [21]. Further study in 
the CSF of HSE patients which compares the inflam-
matory responses in both pleocytosis and normocellu-
lar group is needed to elucidate the pathophysiology of 
HSE.
A retrospective study of 35 HSE patients in Spain over 
a 15 year period revealed that 8 (22.8 %) had normal CSF 
WBC counts [26]. However, all patients in this Spanish 
study had neuroimaging abnormalities but only 92  % 
of patients had PCR positive for HSV. Furthermore, a 
large encephalitis study in Turkey, which recruited 106 
patients between 2001 and 2012, revealed approximately 
15  % of HSE patients had acellular and normocellular 
CSF [5]. The Turkish study also revealed that as many as 
5 % had no MRI lesions.
Our study had some limitations, such as small sample 
size, and lack of complete data in some subjects. How-
ever, the study also revealed important data that directly 
affects the clinical management of HSE. An absence of 
CSF pleocytosis and/or MRI abnormalities does not 
exclude infectious encephalitis, in particular HSE. Addi-
tionally, examination of HSV DNA by PCR in the CSF 
is mandatory in the management of encephalitis. Our 
study indicates that relying on the CSF pleocytosis and/
or presence of classical MRI features of HSE may result in 
a delay in diagnosis and treatment. A larger study is fur-
ther required to confirm results statistically and analyze 
inflammatory responses in normocellular HSE, when 
compared to pleocytosis group, to better understand the 
pathophysiology of HSE.
Conclusion
Absence of CSF pleocytosis in HSE has been described 
as a rare finding in the past, which can distract physi-
cians from the veritable diagnosis. Our study intended to 
demonstrate the extent to which normal CSF WBC find-
ings are found in encephalitis associated with HSV. It is 
not uncommon, and can be found in previously healthy 
patients. Therefore, clinicians should not exclude CNS 
infection (especially HSE) based on the absence of CSF 
pleocytosis and normal neuroimaging.
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